default author photo

Marina Faedi

Scientific Institute for Research, Hospitalization and Healthcare (IRCCS)

Padova

Italy

SCHOLARLY PAPERS

1

DOWNLOADS

76

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

REGOMA: A Randomized, Multicenter, Controlled Open-Label Phase II Clinical Trial of Regorafenib Compared to Lomustine in Relapsed Glioblastoma Patients

Number of pages: 34 Posted: 10 Sep 2018
Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Department of Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Fondazione IRCCS Istituto Neurologico ‘Carlo Besta’, University of Turin, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Azienda Ospedaliera G. Rummo, Azienda Ospedaliera-Universitaria Pisana, Azienda Sanitaria-Universitaria Integrata, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Department of Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Department of Oncology, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), Scientific Institute for Research, Hospitalization and Healthcare (IRCCS), University of Padua - Padua General University Hospital and Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - Department of Oncology
Downloads 76 (830,555)

Abstract:

Loading...

glioblastoma; regorafenib; lomustine; recurrent glioblastoma